Greenyn Biotechnology Co., Ltd

NT$49.00As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6846Healthcare

Country Taiwan

PE (Fwd) 12.39

TSR 4Y CAGR (6.38%)

Div yield —

ROE 13.86%

Biotechnology

Beta (5Y) —

PE TTM 10.44

TSR TTM (28.87%)

Mkt cap NT$1.326B

ROIC 10.87%

SE Grade™

Value

Quality

Moat

1Y Price

Reference

NT$51

4.13%

127.16%

Price below Reference Value

TTM

FYE 31 Dec TWD

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

867.6

RevenueNT$M

—

705.3

800.5

873.2

915.3

892.3

9.08%

—

Revenue growth%

—

13.50

9.09

4.82

(2.52)

9.09

—

48.04

Gross margin%

—

52.59

49.03

47.55

48.07

47.95

48.55

—

18.18

Operating margin%

—

23.63

20.09

19.22

20.63

18.09

20.36

—

14.67

Net margin%

—

20.80

16.32

16.72

15.90

14.55

16.52

—

10.44

P/E ratio (avg)x

—

12.82

18.38

14.55

17.96

12.89

16.25

—

11.09

EV/EBITx

—

9.579

12.84

9.753

14.49

14.76

11.29

—

(25.12)

FCF yield (avg)%

—

11.30

1.57

9.88

(9.04)

(20.86)

5.73

—

(38.46)

FCF margin%

—

30.14

4.71

24.04

(25.80)

(39.13)

14.37

—

(2.623)

FCF / Net incomex

—

1.449

0.289

1.438

(1.623)

(2.690)

0.863

—

10.87

ROIC%

—

60.08

43.65

40.73

25.77

10.27

42.19

—

13.86

Return on equity%

—

26.11

19.23

17.72

15.90

13.65

18.47

—

5.15

Return on assets%

—

17.58

11.25

13.17

6.90

5.12

12.21

—

4.69

EPSNT$

—

5.93

4.99

5.39

4.26

3.80

(10.43%)

—

EPS growth%

—

(15.83)

7.98

(20.94)

(10.79)

(15.83)

—

33.85

Bookvalue per shNT$

—

22.71

30.44

31.43

28.65

28.79

8.05%

—

(12.31)

FCF per shareNT$

—

8.59

1.44

7.75

(6.91)

(10.22)

(5.03%)

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

27.07

Shares (diluted)M

—

24.75

26.18

27.09

34.16

◌34.16

11.34%

—

Buyback yield%

—

(5.79)

(3.48)

(26.08)

◌—

(5.79)

—

1.326

D/E ratiox

—

0.153

0.246

0.077

0.936

1.238

0.199

—

1.750

Enterprise valueNT$B

—

1.597

2.065

1.637

2.735

2.383

19.65%

—

1.201

LT debtNT$B

—

0.862

1.201

—

Peers (US$39.95M)

Cap (US$)

Andros Pharmaceuticals…

40.15M

—

Anti-Microbial Savior…

38.89M

—

Advagene Biopharma Co.…

37.48M

—

Elicio Therapeutics…

39.69M

—

Capital

TTM

10Y

Leveragex

2.684

(1.650)

EBIT/Intx

10.20

104.8

Own earn%

—

Sh yield%

—

(5.79)

Owners

Insiders/Inst%

12.20

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

4/4

Revenue growth years

3/3

EPS growth years

1/3

Dividend streakyrs

Op margin range%

19–24

$1 testx

0.0

Incr. ROIC%

Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

NT$915.3M

9.08%

1.00×

Cost of revenue

NT$475.3M

12.44%

1.10×

Operating expenses

NT$251.2M

7.15%

0.95×

Asset mix

Trend

Other

62.39%

Cash and investments

37.61%

Reinvestment returns

No breakdown available